TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Sponsor: Greenwich LifeSciences, Inc. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 2250 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$5,051,508

Rescue Site Savings

+$3,345,804

Unlock Full NCT05232916 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05232916 Rescue Dossier →